COMMUNIQUÉS West-GlobeNewswire

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
22/07/2024
WESTLAKE VILLAGE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Cell BioEngines Secures an Additional $2 Million in Funding From SOSV and the Empire State Development’s New York Ventures
20/07/2024
NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc., a New York, USA-based company researching stem cells in order to develop new cell therapies unlocked $1.75 million additional funds from SOSV and the [...]
The Alberta Cancer Foundation’s Enbridge Tour Alberta for Cancer Passes $100 Million Milestone in its 16th Year
20/07/2024
Over $7.3 million raised this year alone for Albertans facing cancer in Alberta’s largest cycling fundraiser STRATHMORE, Alberta, July 20, 2024 (GLOBE NEWSWIRE) -- Today, over 1,400 cyclists and their supporters are [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
19/07/2024
SAN CARLOS, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal [...]
Aptose Announces Receipt of Deficiency Notice from Nasdaq
19/07/2024
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral [...]
EDAP Announces Interim Results from Phase 3 Study Evaluating Robotic HIFU for the Treatment of Deep Infiltrating Endometriosis
19/07/2024
Robotic HIFU therapy continues to maintain an excellent safety profile, confirming positive safety data from prior Phase 1 and 2 studies in patients with deep infiltrating endometriosis At three months post procedure, [...]
IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process
19/07/2024
MONTREAL, July 19, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “ Company ” or “ IntelGenx ”) (OTC: IGXT) , a leading drug delivery company focused on the development and manufacturing of pharmaceutical [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19/07/2024
NOVATO, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare [...]
Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
19/07/2024
MIAMI, July 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening [...]
Transparency Notifications from Shareholders
19/07/2024
Transparency Notifications from Shareholders PRESS RELEASE REGULATED INFORMATION 19 July 2024, 06:30 pm CEST Ghent, Belgium – 19 July 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana [...]
BioSenic S.A. : Transparency notification received from Mr François Rieger
19/07/2024
PRESS RELEASE – REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, July 19, 2024, 6pm CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical [...]
BioSenic S.A. : Notification de transparence reçue de la part de Monsieur François Rieger
19/07/2024
COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE Article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes Mont-Saint-Guibert, Belgique, le 19 juillet 2024 à 18h00 CEST – BIOSENIC (Euronext [...]
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
19/07/2024
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital [...]
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
19/07/2024
Daix (France), Long Island City (New York, United States), July 19, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the [...]
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
19/07/2024
Daix (France), Long Island City (New York, Etats-Unis), le 19 juillet 2024 – Inventiva (Euronext Paris et Nasdaq: IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement [...]
Capra Biosciences Lands $7.5 Million Project Agreement To Demonstrate Platform To Rapidly Scale Pharmaceutical Ingredient Manufacturing
19/07/2024
BioMaP-Consortium Project Agreement Will Combine Sustainable Biochemical Production with AI To Demonstrate a Scalable Platform for the Quick Manufacture of Pharmaceutical Ingredients STERLING, Va., July 19, 2024 (GLOBE [...]
Rakovina Therapeutics Announces Second Upsizing of Private Placement
19/07/2024
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, July 19, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a biopharmaceutical [...]
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
19/07/2024
Hamilton, Bermuda, July 19, 2024 (GLOBE NEWSWIRE) -- Study shows significant reduction in aorta dilation, delayed rupture and lower mortality in established animal model of abdominal aortic aneurysm Altamira’s SemaPhore [...]
Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
19/07/2024
GAITHERSBURG, Md., July 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving [...]

Pages